



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 11th November, 2020

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

**Subject: Submission of Standalone Unaudited Financial Results in compliance
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter and Six months ended on 30th September, 2020.
- 2) Limited Review Report by Statutory Auditors on Standalone Unaudited Financial Results for the quarter and six months ended on 30th September, 2020.

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,
For **Norris Medicines Limited**

(Vinay Rana)
Company Secretary



Encl: As above



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002 (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581


Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2020

Sr. No.	Particulars	(Rs. In Lakhs)					
		Quarter Ended			Six Months Ended		Year Ended
		30.09.2020 Unaudited	30.06.2020 Unaudited	30.09.2019 Unaudited	30.09.2020 Unaudited	30.09.2019 Unaudited	31.03.2020 Audited
i	Revenue from Operations	316.49	184.23	176.05	500.72	472.34	784.37
ii	Other Income	0.04	2.45	0.09	2.49	0.79	8.52
iii	Total Revenue (i+ii)	316.53	186.68	176.14	503.21	473.13	792.89
iv	Expenses						
	(a) Cost of Materials Consumed	281.74	3.98	90.77	285.72	244.43	516.30
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	-21.06	89.65	23.11	68.59	32.05	-63.90
	(c) Employee Benefit Expenses	80.51	48.50	78.67	129.01	161.44	322.54
	(d) Finance Costs	27.74	11.11	19.40	38.85	36.87	88.23
	(e) Depreciation and Amortisation Expense	18.00	18.00	17.80	36.00	35.60	72.88
	(f) Other expenditure	58.88	40.71	55.54	99.59	119.89	224.94
	Total Expenses (iv)	445.81	211.95	285.29	657.76	630.28	1160.99
v	Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)	-129.28	-25.27	-109.15	-154.55	-157.15	-368.10
vi	Exceptional items	0	0	0	0	0	0
vii	Profit/ (Loss) before extraordinary items and tax (v-vi)	-129.28	-25.27	-109.15	-154.55	-157.15	-368.10
viii	Extraordinary items	0	0	0	0	0	0
ix	Profit/ (Loss) before Tax (vii-viii)	-129.28	-25.27	-109.15	-154.55	-157.15	-368.10
x	Tax Expense						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-83.99
xi	Profit / Loss after Tax	-129.28	-25.27	-109.15	-154.55	-157.15	-284.11
xii	Other Comprehensive Income	0	0	0	0	0	0
	Total Comprehensive Income for the period	-129.28	-25.27	-109.15	-154.55	-157.15	-284.11
xiii	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
xiv	- Basic and diluted	-1.29	-0.25	-1.09	-1.55	-1.57	-2.84


Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11.11.2020. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 30.9.2020.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited


 Vimal D Shah
 Managing Director

Date: 11.11.2020
 Place: Chennai





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLISHWAR 393 002, (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLISHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Statement of Assets & Liabilities		(Rs. In Lakhs)
	As At 30.09.2020	As At 31.03.2020
	Un audited	(Audited)
A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	791.70	824.99
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.88	0.88
ii) Loans	0.54	0.67
iii) Others	38.80	40.00
e) Non Current Tax Assets (Net)	365.61	365.61
f) Other Non Current Assets	80.08	79.27
TOTAL NON CURRENT ASSETS	1277.61	1311.42
2. Current Assets		
a) Inventories	407.35	400.57
b) Financial Assets		
i) Trade Receivables	200.19	276.06
ii) Cash and Cash Equivalents	3.70	6.35
iii) Bank Balance other than "b" above.		
iv) Loans		
v) Others	76.77	61.21
TOTAL CURRENT ASSETS	688.01	744.19
TOTAL ASSETS	1965.62	2055.61
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.57	992.57
b) Other Equity	-1393.96	-1239.41
Total Equity	-401.39	-246.84
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1497.31	1498.30
b) Provisions		
c) Deferred Tax Liabilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	1497.31	1498.30
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	339.26	293.57
ii) Trade payables	445.18	289.24
iii) Other financial liabilities	34.27	59.44
b) Other Current Liabilities	0.00	0.00
c) Provisions	50.99	161.90
Total Current Liabilities	869.7	804.15
TOTAL EQUITY AND LIABILITIES	1965.62	2055.61






NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Cash flow statement for the half year ended 30th September, 2020		(Rs. In Lakhs)	
		Half Year ended 30.09.2020	For Year Ended 31.03.2020
		Unaudited	Audited
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	-1,54,54,567	-2,84,11,193
	Adjustments for :		
	Depreciation & Amortisation	36,00,000	72,88,208
	Deferred Tax Liability	0	-83,98,936
	Interest Income	-2,49,084	-2,55,750
	Interest Paid	38,84,949	88,22,547
	Profit/Loss on Investment in bonds	0	0
	Profit/Loss on sale of Fixed Assets	0	0
	Other Non Operating Income	0	0
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	-82,18,702	-2,09,55,124
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	75,87,751	25,15,219
	Increase/Decrease in Inventories	-6,78,651	-24,56,026
	Increase/Decrease in Loans & Advances	-15,56,587	-6,38,899
	Trade Payables and Other Liabilities	65,55,169	-73,02,038
	Net cash from operations before taxation	1,19,07,682	-78,81,744
	Tax Paid	0	0
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	1,19,07,682	-78,81,744
	Extra Ordinary Item	0	0
	NET CASH FROM OPERATING ACTIVITIES	36,88,980	-2,88,36,868
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	-2,70,661	-7,73,732
	Sale of Fixed Assets	0	0
	Investments Made during the year	0	0
	Long Term Advances	53,124	5,67,492
	Receipt from Investment	0	0
	Interest Income	2,49,084	2,55,750
	Dividend Received	0	0
	Profit/Loss on sale of bonds	0	0
	Net Cash used in Investing Activities (B)	31,547	49,510
(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	0	0
	Borrowings	-1,00,240	3,74,18,089
	Interest paid	-38,84,949	-88,22,547
	Net Cash Used in Financing Activities (C)	-39,85,189	2,85,95,542
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	-2,64,662	-1,91,816
	Cash and Cash equivalents - Opening balance	6,34,975	8,26,791
	Cash and cash equivalents - Closing balance	3,70,313	6,34,975
		2,64,662	1,91,816
	Component of Cash & Cash Equivalents:		
	Cash on hand	50,000	2,024
	With Banks in Current Accounts	3,20,313	6,32,951
		3,70,313	6,34,975





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the Quarter and half year ended **30th September, 2020**, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019. This Statement, which is the responsibility of the Company's Management and has been Prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (**SRE**) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with IND AS i.e applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMDI/44/2019 dated March 29, 2019 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 11/11/2020

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat



For, H. N. JADAV & Co.
Chartered Accountants

CA HARISHCHANDRA JADAV

Proprietor

M. No. 040525

(Firm Reg. No. 103801W)

UDIN: 20040525AAAACW4689